Apichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application

Stock News

Aug 21

Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug, APH03867 tablets. The company has been issued the Drug Clinical Trial Approval Notice and will commence clinical trials in the near future.

APH03867 is a novel oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1), developed independently by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks uric acid reabsorption in the renal tubules, enhancing uric acid excretion and effectively lowering blood uric acid levels, making it suitable for improving hyperuricemia and gout symptoms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1158851231"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158851231\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158851231?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 11:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158851231","market":"sh","top_or_hot":-1,"title":"Apichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application","media":"Stock News","content":"<p>Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug, APH03867 tablets. The company has been issued the Drug Clinical Trial Approval Notice and will commence clinical trials in the near future.<br><br>APH03867 is a novel oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1), developed independently by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks uric acid reabsorption in the renal tubules, enhancing uric acid excretion and effectively lowering blood uric acid levels, making it suitable for improving hyperuricemia and gout symptoms.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-21 11:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug, APH03867 tablets. The company has been issued the Drug Clinical Trial Approval Notice and will commence clinical trials in the near future.<br><br>APH03867 is a novel oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1), developed independently by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks uric acid reabsorption in the renal tubules, enhancing uric acid excretion and effectively lowering blood uric acid levels, making it suitable for improving hyperuricemia and gout symptoms.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1158851231","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158851231","pubTimestamp":1787284333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","300723":"一品红","PSYK":"PSYK ETF","06978":"永泰生物-B","BK0239":"医药制造","LNGR":"Global X Longevity Thematic ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","BK1161":"生物科技","MEDX":"HORIZON KINETICS MEDICAL ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1574":"生物医药B类股","MDTX":"Corgi MediaTek 2x Daily ETF"},"translate_title":"Apichope 子公司新药试验申请获得监管部门认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"300723":1,"IBBQ":1,"MDTX":1,"MEDX":1,"BMED":1,"PSYK":1,"06978":1,"IBBJ":1,"LNGR":1},"content_text":"Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug, APH03867 tablets. The company has been issued the Drug Clinical Trial Approval Notice and will commence clinical trials in the near future.APH03867 is a novel oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1), developed independently by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks uric acid reabsorption in the renal tubules, enhancing uric acid excretion and effectively lowering blood uric acid levels, making it suitable for improving hyperuricemia and gout symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}